EntreMed Receives Nasdaq Deficie...( ROCKVILLE Md. April 4 2008 /- Ent...)

ROCKVILLE, Md., April 4, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that on April 4, 2008, it received a Deficiency Notice from the Listing Qualifications Department of the NASDAQ Stock Market, LLC. The notice, in accordance with NASDAQ Marketplace Rule 4450(a)(5) "Minimum Bid Price Requirement," stated that the Company's common stock failed to close above the minimum closing bid price of $1.00 per share for 30 consecutive business days. This notification has no immediate effect on the NASDAQ listing or trading of the Company's common stock.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

In accordance with Marketplace Rule 4450(e)(2), EntreMed will have 180 calendar days, or until October 1, 2008, to regain compliance with the minimum $1.00 share bid price requirement. To regain compliance with the minimum bid price requirement, EntreMed's common stock must meet or exceed the $1.00 share price for 10 consecutive business days.

EntreMed intends to actively monitor the bid price for its common stock between now and October 1, 2008, and will consider available options, including a reverse stock split. In order to make available the option of a reverse stock split, EntreMed intends to submit a reverse stock split proposal to its stockholders at the Company's Annual Meeting of Stockholders on June 5, 2008. If a reverse stock split is approved by our stockholders and implemented, it would not only allow the Company to maintain its listing on the NASDAQ Global Market, but facil
'/>"/>